Ichnos Sciences, Glenmark Pharmaceuticals collaborate to accelerate new drug discovery in cancer treatment, ET HealthWorld


New York: Ichnos Sciences Inc and Glenmark Pharmaceuticals Ltd announced the launch of their alliance, Ichnos Glenmark Innovation, to accelerate new drug discovery in cancer treatment. This alliance combines Ichnos’ research and development proficiencies in novel biologics with those of Glenmark in new small molecules to continue developing cutting-edge therapy solutions that treat haematological malignancies and solid tumours.

The newly formed IGI features a robust pipeline of three innovative oncology molecules targeting multiple myeloma, acute myeloid leaukemia, and solid tumours currently undergoing clinical trials. Two of these molecules have received orphan drug designations from the US FDA. Additionally, IGI has two autoimmune disease assets that have been out licensed to leading companies. The alliance will also further explore the in-licensing of late-stage clinical assets to augment its novel oncology drug pipeline.

Harnessing the combined proficiency of over 150 scientists, IGI will leverage the capabilities of its three global centres of innovation. These comprise Ichnos’ headquarters in New York City, NY, US, which is focused on clinical development; the biologics research centre in Lausanne, Switzerland; and Glenmark’s small molecule research centre at Mahape in Mumbai, India.

“Innovation is an integral part of our organisation’s fabric, and through IGI, we are confident of getting closer to our quest to develop a novel cancer drug for the world. Additionally, this will also enhance shareholder value by optimising the cost of development,” remarked Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd.

Cyril Konto, President and CEO, Ichnos Glenmark Innovation, said, “Supported by an experienced leadership and comprising a team that ardently believes in challenging the frontiers of science, IGI seeks to accelerate drug development by combining technologies, expertise, and forces while leveraging Glenmark’s footprint in India. We look forward to joining hands with other like-minded entities, including biotech companies and academia.”

  • Published On Jan 31, 2024 at 02:34 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App


Leave a Reply

Your email address will not be published. Required fields are marked *